

Chimeric receives \$1.62M advance on FY26 R&D tax incentive

Sydney, Australia 29 July 2026: Chimeric Therapeutics (ASX: CHM) (**Chimeric** or the **Company**), a leading Australian cell therapy company is pleased to announce it has received \$1,620,000 from Endpoints Capital under a funding facility secured against Chimeric's anticipated FY26 Research and Development Tax Incentive (**RDTI**).

The \$1.62M received by the Company will support the ongoing Phase 1/2 clinical trial activities and general working capital. The Company is currently undertaking a previously announced Strategic Review and the ability to access funding to support initiatives is a key requirement.

The funding agreement with Endpoints Capital provides Chimeric with early access to a portion of the Company's anticipated FY26 RDTI. The facility is secured against the anticipated FY26 RDTI to be received from the Australian Taxation Office, with interest charged at a commercial rate. Repayment is timed to follow the anticipated receipt of the Company's FY26 RDTI, and is due by 31 December 2026. The facility can be repaid at any time prior to this date, subject to the terms of the facility. Additionally, the principal and interest under the R&D facility with Radium Capital announced on 2 March 2026, has been repaid and discharged.

The Australian Government RDTI program provides companies engaging in eligible activities with a refundable tax offset of up to 43.5%.

Authorised on behalf of the Chimeric Therapeutics Board of Directors.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company is focused on bringing the promise of cell therapy to life for more patients with cancer. Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

For more information visit www.chimerictherapeutics.com or follow us on LinkedIn at www.linkedin.com/company/chimeric-therapeutics.



Contact

Investors

Dr Rebecca McQualter

Chief Executive Officer

Chimeric Therapeutics

E: investors@chimerictherapeutics.com

W: www.chimerictherapeutics.com

Media

Matthew Wright

NWR Communications

T: +61 451 896 420

E: matt@nwrcommunications.com.au